These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28452069)

  • 1. The HDAC6 Inhibitor Tubacin Induces Release of CD133
    Chao OS; Chang TC; Di Bella MA; Alessandro R; Anzanello F; Rappa G; Goodman OB; Lorico A
    J Cell Biochem; 2017 Dec; 118(12):4414-4424. PubMed ID: 28452069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents.
    Namdar M; Perez G; Ngo L; Marks PA
    Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20003-8. PubMed ID: 21037108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tubacin, an HDAC6 Selective Inhibitor, Reduces the Replication of the Japanese Encephalitis Virus via the Decrease of Viral RNA Synthesis.
    Lu CY; Chang YC; Hua CH; Chuang C; Huang SH; Kung SH; Hour MJ; Lin CW
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28468311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of HDAC6 in ischaemia and reperfusion-induced rat retinal injury.
    Yuan H; Li H; Yu P; Fan Q; Zhang X; Huang W; Shen J; Cui Y; Zhou W
    BMC Ophthalmol; 2018 Nov; 18(1):300. PubMed ID: 30453928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone deacetylase-6 inhibitor tubacin directly inhibits de novo sphingolipid biosynthesis as an off-target effect.
    Siow D; Wattenberg B
    Biochem Biophys Res Commun; 2014 Jul; 449(3):268-71. PubMed ID: 24835950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.
    Laino AS; Betts BC; Veerapathran A; Dolgalev I; Sarnaik A; Quayle SN; Jones SS; Weber JS; Woods DM
    J Immunother Cancer; 2019 Feb; 7(1):33. PubMed ID: 30728070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
    Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TGF-β
    Ehnert S; Sreekumar V; Aspera-Werz RH; Sajadian SO; Wintermeyer E; Sandmann GH; Bahrs C; Hengstler JG; Godoy P; Nussler AK
    J Mol Med (Berl); 2017 Jun; 95(6):653-663. PubMed ID: 28271209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase 6 inhibits influenza A virus release by downregulating the trafficking of viral components to the plasma membrane via its substrate, acetylated microtubules.
    Husain M; Cheung CY
    J Virol; 2014 Oct; 88(19):11229-39. PubMed ID: 25031336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetylation of Hsp90 reverses dexamethasone-mediated inhibition of insulin secretion.
    Zhu K; Zhang Y; Zhang J; Zhou F; Zhang L; Wang S; Zhu Q; Liu Q; Wang X; Zhou L
    Toxicol Lett; 2020 Mar; 320():19-27. PubMed ID: 31778773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histone deacetylase inhibitor tubacin mitigates endothelial dysfunction by up-regulating the expression of endothelial nitric oxide synthase.
    Chen J; Zhang J; Shaik NF; Yi B; Wei X; Yang XF; Naik UP; Summer R; Yan G; Xu X; Sun J
    J Biol Chem; 2019 Dec; 294(51):19565-19576. PubMed ID: 31719145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation.
    Haggarty SJ; Koeller KM; Wong JC; Grozinger CM; Schreiber SL
    Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4389-94. PubMed ID: 12677000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDAC6 inhibitors sensitize non-mesenchymal triple-negative breast cancer cells to cysteine deprivation.
    Alothaim T; Charbonneau M; Tang X
    Sci Rep; 2021 May; 11(1):10956. PubMed ID: 34040090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.
    Wang F; Zhong BW; Zhao ZR
    J Biol Regul Homeost Agents; 2018; 32(4):851-858. PubMed ID: 30043566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
    Hideshima T; Qi J; Paranal RM; Tang W; Greenberg E; West N; Colling ME; Estiu G; Mazitschek R; Perry JA; Ohguchi H; Cottini F; Mimura N; Görgün G; Tai YT; Richardson PG; Carrasco RD; Wiest O; Schreiber SL; Anderson KC; Bradner JE
    Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13162-13167. PubMed ID: 27799547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells.
    Rosik L; Niegisch G; Fischer U; Jung M; Schulz WA; Hoffmann MJ
    Cancer Biol Ther; 2014 Jun; 15(6):742-57. PubMed ID: 24618845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models.
    Depetter Y; Geurs S; De Vreese R; Goethals S; Vandoorn E; Laevens A; Steenbrugge J; Meyer E; de Tullio P; Bracke M; D'hooghe M; De Wever O
    Int J Cancer; 2019 Aug; 145(3):735-747. PubMed ID: 30694564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells.
    Aldana-Masangkay GI; Rodriguez-Gonzalez A; Lin T; Ikeda AK; Hsieh YT; Kim YM; Lomenick B; Okemoto K; Landaw EM; Wang D; Mazitschek R; Bradner JE; Sakamoto KM
    Leuk Lymphoma; 2011 Aug; 52(8):1544-55. PubMed ID: 21699378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin.
    Zuo Q; Wu W; Li X; Zhao L; Chen W
    Oncol Rep; 2012 Mar; 27(3):819-24. PubMed ID: 22089141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
    Porter NJ; Mahendran A; Breslow R; Christianson DW
    Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.